Kyunguk Jeong, Seok Won Jang, Se-Ah Jeon, Hei Ji Seo, Se-Hui Kang, Seung-Won Han, Dong In Suh, Sooyoung Lee
{"title":"Efficacy of <i>Bifidobacterium longum</i> and <i>Lactobacillus plantarum</i> (NVP-1703) in Children With Allergic Rhinitis: A Randomized Controlled Trial.","authors":"Kyunguk Jeong, Seok Won Jang, Se-Ah Jeon, Hei Ji Seo, Se-Hui Kang, Seung-Won Han, Dong In Suh, Sooyoung Lee","doi":"10.3346/jkms.2024.39.e266","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>There is increasing evidence that probiotics are effective in treating allergic rhinitis (AR), while some controversies remain. This study was performed to evaluate the therapeutic effect and safety of a mixture of <i>Bifidobacterium longum</i> and <i>Lactobacillus plantarum</i> (NVP-1703) in children with AR.</p><p><strong>Methods: </strong>In a randomized, double-blind, placebo-controlled study, children aged 6 to 19 years with perennial AR were treated with NVP-1703 at a dose of 1 × 10<sup>10</sup> CFU/day or placebo once a day for 4 weeks. Total nasal symptom score (TNSS), nasal symptom duration score (NSDS), quality of life (QoL), allergic inflammatory markers, and safety parameters were evaluated.</p><p><strong>Results: </strong>After 4 weeks of treatment, the TNSS in the NVP-1703 group significantly decreased compared to that in the placebo group (<i>P</i> = 0.011), both in the morning and the evening (<i>P</i> = 0.031 and <i>P</i> = 0.004, respectively). The NSDS also significantly decreased in the NVP-1703 group compared to that in the placebo group (<i>P</i> = 0.018). QoL scores, particularly those related to mouth breathing and itchy nose, showed a significant improvement in the NVP-1703 group compared to the placebo group. The ratios of interleukin (IL)-4/IL-22 and IL-5/IL-22 were significantly reduced in the NVP-1703 group after the treatment compared to the baseline values. No notable adverse events were reported in the NVP-1703 group.</p><p><strong>Conclusion: </strong>Oral administration of a mixture of <i>B. longum</i> and <i>L. plantarum</i> (NVP-1703) improved both AR symptoms and QoL in children with perennial AR, accompanied by decreases in the ratios of T helper 2 cytokines to IL-22.</p><p><strong>Trial registration: </strong>Clinical Research Information Service Identifier: KCT0002661.</p>","PeriodicalId":16249,"journal":{"name":"Journal of Korean Medical Science","volume":"39 40","pages":"e266"},"PeriodicalIF":3.0000,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11496560/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Korean Medical Science","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3346/jkms.2024.39.e266","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background: There is increasing evidence that probiotics are effective in treating allergic rhinitis (AR), while some controversies remain. This study was performed to evaluate the therapeutic effect and safety of a mixture of Bifidobacterium longum and Lactobacillus plantarum (NVP-1703) in children with AR.
Methods: In a randomized, double-blind, placebo-controlled study, children aged 6 to 19 years with perennial AR were treated with NVP-1703 at a dose of 1 × 1010 CFU/day or placebo once a day for 4 weeks. Total nasal symptom score (TNSS), nasal symptom duration score (NSDS), quality of life (QoL), allergic inflammatory markers, and safety parameters were evaluated.
Results: After 4 weeks of treatment, the TNSS in the NVP-1703 group significantly decreased compared to that in the placebo group (P = 0.011), both in the morning and the evening (P = 0.031 and P = 0.004, respectively). The NSDS also significantly decreased in the NVP-1703 group compared to that in the placebo group (P = 0.018). QoL scores, particularly those related to mouth breathing and itchy nose, showed a significant improvement in the NVP-1703 group compared to the placebo group. The ratios of interleukin (IL)-4/IL-22 and IL-5/IL-22 were significantly reduced in the NVP-1703 group after the treatment compared to the baseline values. No notable adverse events were reported in the NVP-1703 group.
Conclusion: Oral administration of a mixture of B. longum and L. plantarum (NVP-1703) improved both AR symptoms and QoL in children with perennial AR, accompanied by decreases in the ratios of T helper 2 cytokines to IL-22.
Trial registration: Clinical Research Information Service Identifier: KCT0002661.
期刊介绍：
The Journal of Korean Medical Science (JKMS) is an international, peer-reviewed Open Access journal of medicine published weekly in English. The Journal’s publisher is the Korean Academy of Medical Sciences (KAMS), Korean Medical Association (KMA). JKMS aims to publish evidence-based, scientific research articles from various disciplines of the medical sciences. The Journal welcomes articles of general interest to medical researchers especially when they contain original information. Articles on the clinical evaluation of drugs and other therapies, epidemiologic studies of the general population, studies on pathogenic organisms and toxic materials, and the toxicities and adverse effects of therapeutics are welcome.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
